Richtlinien zur Einreichung von Proben
Histone Modifications & Enhancer Mapping: The Activation & Repression Switches
Question: Are your target genes actively transcribed, or are they permanently locked within repressive heterochromatin?
To understand how master transcription factors and structural proteins (like CTCF) regulate organoid development, we deploy Cleavage Under Targets and Tagmentation (CUT&Tag). This in situ methodology replaces outdated, low-efficiency ChIP-seq protocols.
Ultra-Low Input Requirement
- CUT&Tag circumvents the need for harsh formaldehyde crosslinking and mechanical sonication, operating efficiently with just 1,000 to 50,000 cells. This drastically reduces the biomass requirement compared to ChIP-seq.
- The Benefit: You can directly profile primary micro-organoids or slow-growing PDOs immediately without spending weeks expanding them in culture—preventing passage-induced epigenetic drift and saving significant reagent costs.
In Situ Cleavage for High Signal-to-Noise
- The pAG-Tn5 transposase tethering mechanism precisely cleaves and tags DNA exclusively at the antibody-bound target sites, eliminating the massive background noise generated by random genomic fragmentation.
- The Benefit: You receive remarkably clean data (FRiP scores of 15%–40%+) at a fraction of the sequencing depth, enabling confident identification of super-enhancers and critical regulatory nodes even in highly heterogeneous 3D models.
We routinely map active promoters (H3K4me3), active enhancers (H3K27ac), transcriptional elongation (H3K36me3), and repressive domains (H3K27me3, H3K9me3) across diverse organoid types.
DNA Methylation Landscapes: The Heritable Silencing & Imprinting Code
Question: Is critical gene silencing driven by stable promoter hypermethylation or dynamic developmental imprinting?
DNA methylation (5mC) is the most fundamental epigenetic mark defining tissue-of-origin and stable cellular identity. Confirming that your organoid accurately reflects the methylation landscape of its parental tissue is a critical QC gateway. We offer three distinct paths, prioritized by your input constraints and genomic resolution needs:
1. Enzymatic Methyl-seq (EM-seq)
Non-Destructive Conversion: EM-seq uses a two-step enzymatic reaction (TET2 oxidation followed by APOBEC3A deamination) rather than harsh chemical sodium bisulfite. Bisulfite treatment destroys >90% of DNA, whereas EM-seq preserves high molecular weight DNA integrity and provides highly uniform coverage across GC-rich regions.
The Benefit: You can obtain complete, whole-genome methylation maps from as little as 100 pg to 10 ng of extracted gDNA. This is the optimal choice for precious organoid samples where DNA yield is severely limited.
2. Whole-Genome Bisulfite Sequencing (WGBS)
When ample DNA (50–200 ng) is available, WGBS remains the historical gold standard.
The Benefit: It provides an unbiased, single-base resolution map across all ~28 million CpG sites in the human genome, ideal for comprehensive methylome discovery and baseline model validation against legacy datasets.
3. Reduced Representation Bisulfite Sequencing (RRBS)
Restriction Enzyme Enrichment: RRBS utilizes MspI digestion to specifically enrich for CpG-dense regions (promoters and CpG islands) prior to conversion. It focuses sequencing power on the most biologically active ~1-10% of the genome.
The Benefit: If you are conducting large-scale high-throughput screening across dozens of organoid lines and only need promoter-level methylation data, RRBS provides a highly cost-effective alternative to WGBS.
Single-Cell Chromatin Accessibility: Resolving Sub-Clonal Heterogeneity
Question: Which distinct sub-clones or differentiating cell types possess the open chromatin necessary to respond to a stimulus?
Bulk epigenetic profiling averages the signal across the entire organoid. However, organoids possess active stem cell niches, fully differentiated epithelial layers, and necrotic cores. To dissect this, we deploy single-cell ATAC-seq (scATAC-seq) and the 10x Genomics Chromium Single Cell Multiome (ATAC + Gene Expression) platform.
- Single-Nucleus Transposition: We isolate intact nuclei and perform Tn5 tagmentation in bulk before partitioning them into tens of thousands of individual droplets using transcript-specific barcodes. This maps the exact regions of open, accessible chromatin independently for every single cell.
- The Benefit: You can definitively link a specific open enhancer to a rare, drug-resistant cancer sub-clone or a transient developmental progenitor, ensuring that critical lineage-driving regulatory elements are not lost in the background noise of the dominant cell types.
Multi-Omics Regulatory Network Integration
Question: How do chromatin state changes directly translate into downstream gene expression?
Epigenetic data is most powerful when linked directly to transcriptomic output. CD Genomics offers advanced multi-omics integration pipelines. We computationally fuse your CUT&Tag or scATAC-seq data with parallel bulk RNA sequencing or scRNA-seq data.
Using advanced modeling frameworks (e.g., Pando or SCENIC+), we construct comprehensive Gene Regulatory Networks (GRNs). This allows you to trace a complete biological circuit: from the binding of a master transcription factor, to the opening of a specific enhancer, to the upregulation of the target mRNA—providing irrefutable mechanistic evidence for your drug target or developmental pathway.
Organoid-Specific Sample Preparation & Rigorous QC Gateways
Epigenetic profiling fails if sample preparation is flawed. Organoids embedded in Matrigel present severe biochemical hurdles: residual matrix sequesters primary antibodies, blocks enzymatic transposition, and ruins cell-bead binding.
Proprietary Extraction Protocols
- Cold-Depolymerization Matrigel Removal: Instead of aggressive enzymatic shearing that destroys cell surface proteins and ruptures fragile nuclei, we utilize specialized cold-recovery solutions (4°C) to liquefy extracellular matrices.
- Gentle Dissociation: We utilize non-shearing enzymatic reagents coupled with optimized digitonin permeabilization to guarantee >95% viable, debris-free intact nuclei.
The 4-Tier Quality Control System
Your project is gated by stringent QC checks at every critical phase:
- Intake QC: Nuclear membrane integrity validation via AO/PI staining and Qubit fluorometry.
- Reaction QC: Spike-in controls (e.g., recombinant designer nucleosomes) in CUT&Tag monitor quantitative recovery.
- Library QC: TapeStation profiling confirms mononucleosomal fragmentation (~300 bp).
- Bioinformatic QC: Assessment of alignment rates, duplication ratios, and FRiP.
Method Selection & "Best for / Not for" Boundaries
To ensure your budget and samples are allocated correctly, our scientific team strictly enforces the following application boundaries when routing your project through our organoid sequencing and analysis services:
| Technology | Best For | Not Recommended For |
|---|---|---|
| CUT&Tag | Profiling histone marks and TFs from rare or primary un-passaged organoids (1,000–50,000 cells) where sample conservation is paramount. | Direct profiling of highly insoluble cytoplasmic structural proteins, or targets lacking highly specific, ChIP-validated antibodies. |
| EM-seq | Extracting uniform, whole-genome methylation maps from extremely precious micro-organoid pellets (<10 ng DNA) without risking bisulfite degradation. | Projects with ample, highly robust DNA where legacy WGBS workflows have already established extensive historical cohort baselines. |
| RRBS | Cost-effective, high-throughput screening of promoter-level methylation changes across dozens of distinct organoid drug-response lines. | Discovery-phase studies aiming to identify novel methylation changes in deep intergenic regions or distal super-enhancers. |
| scATAC-seq | Resolving the exact regulatory elements driving rare sub-clonal populations (e.g., stem cell niches) within a highly heterogeneous organoid structure. | Homogenous, fully differentiated 2D monocultures where bulk ATAC-seq offers a faster, more economical snapshot of overall accessibility. |
References:
- Zenk F, Fleck JS, et al. Single-cell epigenomic reconstruction of developmental trajectories from pluripotency in human neural organoid systems. Nature Neuroscience. 2024;27:1437–1448.
- Wang R, Mao YN, et al. Systematic evaluation of colorectal cancer organoid system by single-cell RNA-Seq analysis. Genome Biology. 2022;23(1):106.
- Kraiczy J, Nayak KM, et al. DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development. Genome Biology. 2019;20(1):19.
- Zhang Y, Wang L, et al. Super-enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5-FU Resistance in Gastric Cancer. Advanced Science. 2024;12(7):2409050.
- Kaya-Okur HS, Wu SJ, et al. Targeted in situ genome-wide profiling with high efficiency for low cell numbers. Nature Communications. 2019;10:1930.
For research use only. Not for use in diagnostic procedures, clinical decision-making, patient stratification, therapeutic selection, or clinical trials.
Epigenetic Profiling Demos
Figure 1. CUT&Tag analysis mapping dynamic H3K27ac and H3K4me3 modifications to identify super-enhancers driving organoid lineage commitment. The ultra-low input workflow preserves epigenetic signatures that would be lost to culture adaptation in traditional ChIP-seq.
Figure 2. DNA Methylation mapping via EM-seq. By avoiding bisulfite-induced DNA degradation, EM-seq maintains high-molecular-weight DNA integrity and delivers robust CpG coverage even from micro-organoid pellets containing less than 10 ng of gDNA.
Figure 3. Resolving sub-clonal heterogeneity with scATAC-seq. Single-cell mapping of open chromatin regions allows researchers to distinctly track developmental trajectories and isolate drug-resistant niches from the broader organoid population.
Case Study: Profiling Super-Enhancer Dynamics in Gastric Cancer Organoids
Source: Zhang et al., Advanced Science, 2024. (CC BY 4.0) [4]
Background: Researchers investigating gastric cancer required an advanced model to study resistance to the chemotherapy drug 5-fluorouracil (5-FU). They generated patient-derived organoids (PDOs) but needed to understand the epigenetic mechanisms driving the resistant phenotype, which lacked obvious genetic mutations.
Methods: The team applied CUT&Tag directly to the gastric cancer PDOs, targeting the active histone mark H3K27ac and specific transcription factors. The low-input capability of CUT&Tag was essential due to the limited biomass of the early-passage organoid models.
Figure 4. Identifying epigenetic drivers of drug resistance. CUT&Tag revealed robust H3K27ac peaks marking super-enhancers unique to 5-FU resistant organoid sub-clones.
Results: The H3K27ac profiling mapped massive chromatin remodeling and identified the activation of a critical super-enhancer (SE). This SE directly upregulated the master transcription factor NR3C1. The CUT&Tag data definitively proved that the resistant phenotype was driven by this epigenetic switch, not genomic alteration.
Conclusion: By utilizing CUT&Tag on 3D organoids, the researchers established a direct mechanistic link to chemoresistance and successfully demonstrated that pharmacological disruption of this super-enhancer (using a BET bromodomain inhibitor) re-sensitized the organoids to 5-FU.
Organoid Epigenetic FAQs
1. Can I submit flash-frozen organoid pellets for CUT&Tag?
Flash-freezing standard cell pellets without cryoprotectants often ruptures nuclear membranes during the thawing process, which severely increases non-specific background in CUT&Tag. We strongly recommend slow-freezing viable cells in specialized cryopreservation media or utilizing our proprietary low-toxicity nuclear extraction buffers prior to freezing.
2. How do you distinguish between organoid DNA and contaminating Matrigel/mouse DNA?
Matrigel contains trace amounts of mouse DNA. During bioinformatic processing, all reads are strictly aligned against a dual human/mouse reference genome (e.g., hg38/mm10). Reads mapping unambiguously to the mouse genome are computationally discarded before peak calling or methylation extraction to prevent false-positive annotations.
3. If my organoid cell count is below 1,000 cells, can I still perform epigenetic profiling?
While bulk CUT&Tag performs optimally above 1,000 cells, we offer specialized single-cell CUT&Tag (scCUT&Tag) and scATAC-seq workflows that utilize droplet microfluidics or combinatorial indexing to generate profiles from ultra-scarce populations. Please consult our technical team for a pilot feasibility study.
4. Why do you require a ChIP-validated antibody for CUT&Tag?
CUT&Tag relies on the primary antibody to tether the pAG-Tn5 enzyme precisely to the target chromatin. If the antibody has high off-target affinity (cross-reactivity) or fails to bind the native chromatin structure, the transposase will cleave random DNA, destroying the signal-to-noise ratio. Only highly specific, ChIP-validated antibodies guarantee reliable tagmentation.
5. How long does the organoid epigenetic profiling workflow take?
Turnaround times vary based on the selected modality and bioinformatic integration depth. Standard EM-seq or CUT&Tag projects typically require 3–5 weeks from sample receipt to data delivery. Highly integrated multi-omics projects (e.g., scATAC-seq + scRNA-seq) may require 6–8 weeks.